Humanized CD38 Antibody Engineering for Multiple Myeloma Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for multiple myeloma, such as traditional chemotherapy and radiotherapy, are inadequate, and there is a lack of effective antibody therapies targeting CD38 in China.
Innovation Solution
Development of a murine, chimeric, and humanized antibodies specifically binding to human CD38, along with their antigen-binding fragments, through hybridoma preparation, screening, and purification, and their use in pharmaceutical compositions for treating multiple myeloma and other CD38-related diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional chemotherapy and radiotherapy are used for multiple myeloma treatment, then treatment options are available, but treatment effectiveness is insufficient
Solution Approach 1:
The patent changes the therapeutic parameter from traditional chemotherapy/radiotherapy to antibody-based therapy targeting CD38. The antibody (50G12) binds specifically to CD38 on myeloma cells, altering the mechanism of action and achieving superior treatment effectiveness with improved adaptability to different patient profiles.
2Ease of manufacture
If no CD38-targeting antibody therapy is available in China, then import restrictions are avoided, but therapeutic demand cannot be met
Solution Approach 1:
The patent enables self-service by developing and producing the CD38-targeting antibody therapy domestically in China. The complete technical solution including antibody preparation, purification, and formulation allows Chinese pharmaceutical industries to independently produce the therapy, eliminating dependence on imports while meeting therapeutic demand.
3Measurement precision
If murine antibody is used for CD38 targeting, then high binding affinity is achieved, but immunogenicity issues arise
Solution Approach 1:
The patent uses an intermediary approach by developing chimeric antibodies that combine mouse antibody framework (providing high binding affinity) with human antibody constant regions (reducing immunogenicity). This intermediary structure allows the antibody to maintain its high affinity for CD38 while minimizing harmful immunogenic responses in human patients.
4Manufacturing precision
If antibody therapy is developed for CD38, then treatment specificity is improved, but development complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the antibody development process into distinct modular components: antigen immunization, hybridoma preparation, antibody screening, chimeric/humanized antibody construction, and clinical validation. This segmented approach manages the complexity of antibody therapy development by breaking it down into manageable stages with clear objectives and deliverables.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The developed antibodies demonstrate high affinity and biological activity, including ADCC and CDC, significantly prolonging survival time in animal models and offering a promising therapeutic option for multiple myeloma and other CD38-related diseases.
Implementation Method 1
screened and obtained murine antibody that specifically binds to human CD38
Implementation Method 2
biological activity identification, including ADCC and CDC
Implementation Method 3
biological activity identification, including ADCC and CDC
Data Source
AI summary
An antibody or an antigen-binding fragment thereof that binds to human CD38. The antibody or the antigen-binding fragment thereof can effectively bind to human CD38 and is applied to preparing a drug for treating diseases having strong CD38 expression such as multiple myeloma.